10-O-tert-butyl 4-O-methyl (1R,4R,12S)-4-methyl-3,7-dioxo-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4,10-dicarboxylate | 157035-50-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 10-O-tert-butyl 4-O-methyl (1R,4R,12S)-4-methyl-3,7-dioxo-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4,10-dicarboxylate
• CAS: 157035-50-2
• 化学式: C₁₉H₂₂N₂O₆
• 分子量: 374.393
• InChiKey: NSZNYVJEADQKLA-VUXJGSIMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  10-O-tert-butyl 4-O-methyl (1R,4R,12S)-4-methyl-3,7-dioxo-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4,10-dicarboxylate 在 三氟甲磺酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以46%的产率得到
  参考文献：
  名称：

  (+)-Duocarmycin A,epi-(+)-Duocarmycin A 及其非天然对映体的全合成：化学和生物学特性评估

  摘要：

  描述了 (+)-duocarmycin A (1) 的对映选择性全合成的全部细节，其中提供了控制远程立体中心的相对和绝对立体化学的解决方案。采用 15 的催化不对称二羟基化来引入活化环丙烷所需的绝对立体化学，并采用 61 的非对映选择性 Dieckmann 型缩合来控制 C6 季中心的绝对立体化学。61 的热力学与动力学缩合的互补非对映选择性允许从常见中间体合成 (+)-duocarmycin A 或表 - (+)-duocarmycin A。反应性环丙烷的最终引入是通过甲磺酸酯 44 在用碱处理或直接从相应的游离醇本身、duocarmycin D1 (42) 处理后，在 Mitsunobu 活化后的跨环螺环化来完成的。值得注意的是，使用 (DHQD)2-PHAL/(DHQ)2-PHAL 的 15 的不对称二羟基化...

  DOI：

  10.1021/ja962431g
• 作为产物：
  描述：

  (2R,8S)-4-(benzyloxy)-3,6-bis(tert-butyloxycarbonyl)-8-[(tert-butyldimethylsilyl)oxy]-1-imino-2-methyl-2-[[(4S)-2-oxo-4-isopropyloxazolidin-3-yl]carbonyl]-2,3,6,7,8,9-hexahydro-1H-pyrrolo[3,2-f]quinoline 在 palladium on activated charcoal 吡啶 、 盐酸 、 甲醇 、 lithium methanolate 、 水 、 氢气 、 对甲苯磺酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 12.5h， 生成 10-O-tert-butyl 4-O-methyl (1R,4R,12S)-4-methyl-3,7-dioxo-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4,10-dicarboxylate
  参考文献：
  名称：

  (+)-Duocarmycin A,epi-(+)-Duocarmycin A 及其非天然对映体的全合成：化学和生物学特性评估

  摘要：

  描述了 (+)-duocarmycin A (1) 的对映选择性全合成的全部细节，其中提供了控制远程立体中心的相对和绝对立体化学的解决方案。采用 15 的催化不对称二羟基化来引入活化环丙烷所需的绝对立体化学，并采用 61 的非对映选择性 Dieckmann 型缩合来控制 C6 季中心的绝对立体化学。61 的热力学与动力学缩合的互补非对映选择性允许从常见中间体合成 (+)-duocarmycin A 或表 - (+)-duocarmycin A。反应性环丙烷的最终引入是通过甲磺酸酯 44 在用碱处理或直接从相应的游离醇本身、duocarmycin D1 (42) 处理后，在 Mitsunobu 活化后的跨环螺环化来完成的。值得注意的是，使用 (DHQD)2-PHAL/(DHQ)2-PHAL 的 15 的不对称二羟基化...

  DOI：

  10.1021/ja962431g

文献信息

• Synthesis and Properties of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Methoxy-1,2,9,9a-tetrahydrocyclopropa[<i>c</i>]benz[<i>e</i>]indol-4-one (MCBI) Alkylation Subunit:  Magnitude of Electronic Effects on the Functional Reactivity
  作者：Dale L. Boger、Jeffrey A. McKie、Hui Cai、Barbara Cacciari、P. G. Baraldi

  DOI：10.1021/jo952033g

  日期：1996.1.1

  radical-alkene cyclization (24 --> 25, 32 --> 33) for completion of the synthesis of the 1,2-dihydro-3H-benz[e]indole skeleton and final Ar-3' alkylation of 28 for introduction of the activated cyclopropane. Two approaches to the implementation of the key 5-exo-trig free radical cyclization are detailed with the former proceeding with closure of 24 to provide 25 in which the required product functionalization was

  在以下文献中描述了7-甲氧基-1,2,9,9a-四氢环丙烷[c]苯并[e]吲哚-4-酮（MCBI）的合成，MCBI是带有对C4羰基的C7甲氧基的取代的CBI衍生物。努力确定对试剂的化学和功能反应性的潜在电子效应的大小。通过修饰的Stobbe缩合/ Friedel-Crafts酰化反应制备MCBI烷基化亚基的核心结构，以生成适当官能化的萘前体（15和20），然后进行5-exo-trig芳基自由基-烯烃环化（24-> 25、32-> 33）完成1，2-二氢-3H-苯并[e]吲哚骨架的合成，最后28的Ar-3'烷基化，以引入活化的环丙烷。详细介绍了实现关键的5-exo-trig自由基环化的两种方法，前者以24结束，以提供25，其中在环化之前引入了所需的产品功能化，而后者则用了环化产物的Tempo捕集器官能化的未反应的烯烃底物32提供33％。后一种简洁的方法以极好的总转化率（27-30％）以12-
• Synthesis and Evaluation of CC-1065 and Duocarmycin Analogues Incorporating the Iso-CI and Iso-CBI Alkylation Subunits:  Impact of Relocation of the C-4 Carbonyl
  作者：Dale L. Boger、Robert M. Garbaccio、Qing Jin

  DOI：10.1021/jo971686p

  日期：1997.12.1

  The synthesis of 2-(tert-Butyloxycarbonyl)-1, 2, 9, 9a-tetrahydrocyclopropa[c]benzo[f]indol-8-one (31, N-BOC-iso-CBI) and 1-(tert-Butyloxycarbonyl)-4-hydroxy-3-[[(methanesulfonyl)oxy]methyl]-2, 3-dihydroindole (19, seco-N-BOC-iso-CI) containing an isomeric structural modification in the CC-1065 and duocarmycin alkylation subunits and their incorporation into analogues of the natural products are detailed. The approach was based on a directed ortho metalation of an appropriately functionalized benzene (13) or naphthalene (24) precursor to regiospecifically install iodine at the C-2 position. Conversion of these respective intermediates to the dihydroindole skeleton utilized an established 5-exo-trig aryl radical cyclization onto an unactivated alkene with subsequent TEMPO trap or the more recent 5-exo-trig aryl radical cyclization onto a vinyl chloride for direct synthesis of the immediate precursors. Closure of the activated cyclopropane to complete the iso-CBI nucleus was accomplished by a selective ortho spirocyclization. The evaluation of the iso-CBI-based agents revealed a significant stability comparable to that of CC-1065 and duocarmycin A, but that it is more reactive than duocarmycin SA (6 - 7x) or the direct comparison CBI-based agents (5x) for which X-ray structure comparisons served to establish the basis for their inherent reaction regioselectivity and reactivity. Resolution and synthesis of a full set of natural product analogues and subsequent evaluation of their DNA alkylation properties revealed that the iso-CBI analogues, even with the relocation of the C-4 carbonyl and the most substantial structural modifications to the alkylation subunit to date, reacted at comparable rates and retain the identical and characteristic sequence selectivity of CC-1065 and the duocarmycins. This observation is inconsistent with the proposal that a sequence-dependent C-4 carbonyl protonation by strategically located DNA backbone phosphates controls the DNA alkylation selectivity but is consistent with the proposal that it is determined by the AT-rich noncovalent binding selectivity of the agents and the steric accessibility of the N3 alkylation site. Confirmation that the DNA alkylation reaction is derived from adenine N3 addition to the least substituted carbon of the activated cyclopropane, and its quantitation (95%) was established by isolation and characterization of the depurination adenine N3 adduct. Consistent with past studies and despite the deep-seated structural change in the alkylation subunit, the agents were found to exhibit potent cytotoxic activity that correlates with their inherent reactivity.
• A comparative study of the solvolysis reactivity, regioselectivity, and stereochemistry of the duocarmycin a and sa alkylation subunits
  作者：Dale L. Boger、Joel Goldberg、Jeffrey A. McKie

  DOI：10.1016/0960-894x(96)00346-0

  日期：1996.8

  The comparative solvolysis reactivity, regioselectivity, and stereochemistry of N-BOC-DSA (4) and N-BOC-DA (5), simple derivatives of the DNA alkylation subunits of duocarmycin SA and A, are detailed. Most important of the observations is the substantially greater reactivity of 5 versus 4 (16x), the modest regioselectivity of both 4 (6.5-4:1) and 5 (1.5:1), and the establishment that the abnormal ring expansion solvolysis proceeds by S(N)2 addition to the activated cyclopropane with clean inversion of the reacting center stereochemistry. Copyright (C) 1996 Elsevier Science Ltd
• Total Synthesis of (+)-Duocarmycin A, <i>epi</i>-(+)-Duocarmycin A and Their Unnatural Enantiomers:  Assessment of Chemical and Biological Properties
  作者：Dale L. Boger、Jeffrey A. McKie、Takahide Nishi、Tsuyoshi Ogiku

  DOI：10.1021/ja962431g

  日期：1997.1.1

  was employed to control the absolute stereochemistry of the C6 quaternary center. The complementary diastereoselectivity of a thermodynamic versus kinetic condensation of 61 permitted the divergent synthesis of (+)-duocarmycin A or epi-(+)-duocarmycin A from common intermediates. Final introduction of the reactive cyclopropane was accomplished by transannular spirocyclization of the mesylate 44 upon treatment

  描述了 (+)-duocarmycin A (1) 的对映选择性全合成的全部细节，其中提供了控制远程立体中心的相对和绝对立体化学的解决方案。采用 15 的催化不对称二羟基化来引入活化环丙烷所需的绝对立体化学，并采用 61 的非对映选择性 Dieckmann 型缩合来控制 C6 季中心的绝对立体化学。61 的热力学与动力学缩合的互补非对映选择性允许从常见中间体合成 (+)-duocarmycin A 或表 - (+)-duocarmycin A。反应性环丙烷的最终引入是通过甲磺酸酯 44 在用碱处理或直接从相应的游离醇本身、duocarmycin D1 (42) 处理后，在 Mitsunobu 活化后的跨环螺环化来完成的。值得注意的是，使用 (DHQD)2-PHAL/(DHQ)2-PHAL 的 15 的不对称二羟基化...